Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
100%
Immunization Programs
100%
Pneumococcal Conjugate Vaccine
100%
Gambia
100%
Infant Immunization
100%
Illness
57%
Pneumococcal Vaccine
57%
Vaccine Trial
42%
Valent
42%
Vaccination
28%
Study within a Trial
28%
Public Provider
28%
Provider Perspectives
28%
Randomized Placebo-controlled Trial
14%
Clinical Trials
14%
Study Support
14%
Developing Countries
14%
Multi-dose Vials
14%
West Africa
14%
Treatment Costs
14%
DALYs Averted
14%
Infant Vaccination
14%
Cohort Model
14%
Differences in Distributions
14%
Incremental Cost
14%
Vaccine Program
14%
Vaccination Program
14%
Disease Burden
14%
Routine Immunization
14%
Pneumococcal Disease
14%
Static Model
14%
Direct Benefits
14%
Cost-effectiveness Study
14%
Intention-to-treat
14%
Sub-Saharan Africa
14%
Cost-effective Vaccines
14%
Sub-Saharan African Countries
14%
Incremental Cost-effectiveness Ratio
14%
Direct Costs
14%
95% Confidence Interval
14%
Cost per DALY
14%
Preventable Deaths
14%
Medicine and Dentistry
Health Care Cost
100%
Pneumococcus Vaccine
100%
Diseases
45%
Placebo
9%
Clinical Trial
9%
Single Drug Dose
9%
House Dust Mite Allergen Extract
9%
Serotype
9%
Intention-to-Treat Analysis
9%
Effectiveness Study
9%
Disease Burden
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pneumococcus Vaccine
100%
Diseases
75%
Vaccination
25%
Placebo
12%
Clinical Trial
12%
Effectiveness Study
12%
House Dust Mite Allergen Extract
12%